Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alzamend Neuro Inc
(NQ:
ALZN
)
3.080
-0.310 (-9.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alzamend Neuro Inc
< Previous
1
2
3
Next >
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
August 19, 2024
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
August 19, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
August 12, 2024
Major Depressive Disorder (MDD) was the third leading cause of global disease burden in 2008, according to the World Health Organization, with projections that it could become the leading cause by...
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
August 12, 2024
Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be...
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
August 12, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
August 06, 2024
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves...
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder and Alzheimer’s Disease
August 06, 2024
Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide.1 Rising cases has led to an uptick in new treatments moving through the clinical...
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
August 06, 2024
Alzamend Neuro, Inc. (Nasdaq:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
August 05, 2024
Alzamend Neuro, Inc. (NASDAQ:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease
Via
PressReach
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
August 06, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
August 05, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
July 31, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Reverse Stock Split
July 12, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
May 22, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Initial Closing of Private Placement
May 14, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
May 09, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
May 07, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
December 11, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
November 20, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
November 16, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
November 13, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Reverse Stock Split
October 30, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
October 23, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
October 02, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
September 22, 2023
From
Alzamend Neuro
Via
Business Wire
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
August 30, 2023
From
Alzamend Neuro
Via
Business Wire
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
June 22, 2023
From
Alzamend Neuro
Via
Business Wire
Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference
June 13, 2023
From
Alzamend Neuro
Via
Business Wire
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 04, 2023
From
Ault Alliance, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.